This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/chebi/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01426/identifier/kegg-compound/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01426
rdf:type
n5:Drug
n5:description
An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.
n5:generalReferences
# Brugada J, Brugada P, Brugada R: The ajmaline challenge in Brugada syndrome: a useful tool or misleading information? Eur Heart J. 2003 Jun;24(12):1085-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12804922
n5:group
approved
n5:indication
For use as an antiarrhythmic agent.
owl:sameAs
n14:DB01426 n15:DB01426
dcterms:title
Ajmaline
adms:identifier
n11:PA164776839 n12:Ajmaline n16:28462 n17:D00199 n18:DB01426 n19:C06542
n5:mechanismOfAction
The class I antiarrhythmic agents interfere with the sodium channel. A class IA agent lengthens the action potential (right shift) which brings about improvement in abnormal heart rhythms. This drug in particular has a high affinity for the Nav 1.5 sodium channel.
n5:synonym
(5AR,6S,8S,10S,11S,11as,12ar,13R)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5H-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol Ajmalin (+)-Ajmaline
n5:synthesisReference
Ivan F. Makarevich, Yaroslav I. Khadzhai, Valeria V. Pavlova, Anastasia V. Nikolaeva, "Cardenolide and bufadienolide derivatives of ajmaline and process for producing same." U.S. Patent US4175078, issued May, 1975.
n7:hasConcept
n8:M0000613
n5:IUPAC-Name
n6:271B496E-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4974-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4973-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4970-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4971-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4972-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B496C-363D-11E5-9242-09173F13E4C5 n6:271B4984-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B496D-363D-11E5-9242-09173F13E4C5 n6:271B496A-363D-11E5-9242-09173F13E4C5 n6:271B4986-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B496B-363D-11E5-9242-09173F13E4C5 n6:271B4987-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:C01BA05
n5:H-Bond-Acceptor-Count
n6:271B497A-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B497B-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4975-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4976-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4978-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4977-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4979-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
4360-12-7
n5:category
n5:Bioavailability
n6:271B4980-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4982-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4983-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4985-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B497F-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B497E-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4981-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B496F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B497C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B497D-363D-11E5-9242-09173F13E4C5